About lab
A four-compartment pharmacokinetic model that describes the disposition of losartan and E-3174 (Karatza and Karalis, 2020). The main objective of this model is to describe the secondary maxima observe.
Runtime
Duration24
Comms Step1
Runs
Total0
Completed0
Failed0
Metadata
Packagekaratzakaralis2020-cyp-mediated-losartan-metabolism-lab
Created2026-05-16
Updated2026-05-16
pharmacologymetabolismcyp-metabolismpharmacokineticscardiovascularsbmltelluriumfaithfulbiomodels_ebivisualisation
Manifest
{
"io": {
"inputs": [
{
"name": "losartan_oral_dose",
"label": "Losartan Oral Dose",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_oral_dose"
},
{
"name": "cyp2c9_metabolism_start_time",
"label": "CYP2C9 Metabolism Start Time",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.cyp2c9_metabolism_start_time"
},
{
"name": "initial_losartan_stomach",
"label": "Initial Losartan Stomach",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.initial_losartan_stomach"
}
],
"outputs": [
{
"name": "state",
"label": "Tracked source state",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.state"
},
{
"name": "summary",
"label": "Simulation summary",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.summary"
},
{
"name": "species_labels",
"label": "Observable labels",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.species_labels"
},
{
"name": "losartan_cellular_compartment",
"label": "Losartan Cellular Compartment",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_cellular_compartment"
},
{
"name": "losartan_intracellular",
"label": "Losartan Intracellular",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_intracellular"
},
{
"name": "losartan_outflow",
"label": "Losartan Outflow",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_outflow"
},
{
"name": "losartan_portal_compartment",
"label": "Losartan Portal Compartment",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_portal_compartment"
},
{
"name": "losartan_stomach",
"label": "Losartan Stomach",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.losartan_stomach"
},
{
"name": "e3174_outflow",
"label": "E3174 Outflow",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.e3174_outflow"
},
{
"name": "e3174_cellular_compartment",
"label": "E3174 Cellular Compartment",
"maps_to": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.e3174_cellular_compartment"
}
]
},
"tags": [
"pharmacology",
"metabolism",
"cyp-metabolism",
"pharmacokinetics",
"cardiovascular",
"sbml",
"tellurium",
"faithful",
"biomodels_ebi"
],
"title": "KaratzaKaralis2020 - CYP mediated losartan metabolism Lab",
"models": [
{
"path": "owned/models/pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model",
"alias": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model",
"parameters": {
"model_path": "data/MODEL2412180001.xml",
"integration_step": 0.1
},
"provenance": {
"owned_path": "owned/models/pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model"
}
},
{
"path": "owned/models/visualisation",
"alias": "visualisation",
"provenance": {
"owned_path": "owned/models/visualisation"
}
}
],
"wiring": [
{
"to": [
"visualisation.pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model_state"
],
"from": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.state"
},
{
"to": [
"visualisation.pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model_summary"
],
"from": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.summary"
},
{
"to": [
"visualisation.pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model_species_labels"
],
"from": "pharmacology_sbml_karatzakaralis2020_cyp_mediated_losartan_metabol_model2412180001_model.species_labels"
}
],
"runtime": {
"duration": 24,
"initial_inputs": {},
"communication_step": 1
},
"description": "A four-compartment pharmacokinetic model that describes the disposition of losartan and E-3174 (Karatza and Karalis, 2020). The main objective of this model is to describe the secondary maxima observe.",
"schema_version": "2.0"
}Sign in to start your own run. Public-lab history stays visible here.
Select a run from History to view its results.